Articles Archives - QualityStocks

TuesdaySep 01, 2026 9:45 am

Drone Detection and Vital Life Signs Monitoring Help Silynx’s In-Ear Tactical Communication Systems Support Those on the Front Lines

Silynx’s in-ear tactical communication system amplifies drone-related frequencies, allowing the operator to hear an approaching drone sooner, a capability the company first brought to market in 2024. Silynx is developing an in-ear headset being built into the company’s existing platform, requiring no additional worn devices, and designed to transmit vital life signs alerts to commanders and command centers even when the user is incapacitated. Silynx's long-standing supplier relationships reflect a sustained track record with demanding customers, and capabilities like drone detection are how the company continues to earn that position. Whether you’re in the military, law enforcement, riot control, or…

TuesdaySep 01, 2026 9:00 am

HWAL Inc. (HWAL) Builds a Company from Master Tapes to Multimedia Entertainment

Music preservation is not a hypothetical problem, and digital distribution further complicates the issue. Through its subsidiary Melody Trust, HWAL holds rights to master recordings from an array of artists. HWAL has reached beyond simple licensing to new artist development. Streaming apps shuffle through millions of songs in seconds, yet almost nobody asks who is actually protecting the original master recordings once the algorithm moves on. HWAL (OTC: HWAL) is a holding company built around that exact question. Through its subsidiary Melody Trust and “Lunar Records”, a jointly held company with SI Blue Foundation (Space Blue), the company curates, licenses…

FridayAug 28, 2026 9:45 am

Gold’s Resilience Signals a Changing Market as Lahontan Gold Advances Santa Fe Toward Potential 2027 Restart

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Gold has demonstrated remarkable resilience despite periodic pressure from higher bond yields, while central-bank buying, geopolitical uncertainty and concerns surrounding currencies and sovereign debt continue supporting demand for the precious metal. China's move to restrict certain retail paper-gold products could further reshape investor demand, although the long-term impact on physical gold remains uncertain. For Lahontan Gold, a sustained gold market could provide an important backdrop as the company advances its flagship Santa Fe Mine toward a potential return to production in 2027 following a…

FridayAug 28, 2026 9:00 am

SS Innovations International Inc. (NASDAQ: SSII) Indian Surgical Robotics Growth Points to Broader Market Opportunity

SS Innovation’s SSi Mantra system was used in more than 50 robotic surgeries in a single day at Mohak Bariatrics and Robotics in Indore, highlighting growing clinical utilization in India. The milestone comes as SS Innovations reports 224 SSi Mantra systems installed across 12 countries, providing a growing installed base for future procedure and instrument revenue. Second-quarter 2026 installations reached 30 systems, above the 25 systems modeled by the analyst cited in the supplied report. Quarterly revenue reached $13.9 million, up 39% year over year, while system sales increased 41% to $12.4 million. FDA review of the SSi Mantra 510(k)…

ThursdayAug 27, 2026 1:30 pm

VERAXA Biotech AG (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology

VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance. The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration. AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells. VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy. The collaboration adds to VERAXA’s growing partnering track record, which also…

ThursdayAug 27, 2026 12:45 pm

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage. With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair. Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? Researchers are pursuing that question through…

WednesdayAug 26, 2026 10:30 am

Numa Numa Resources Inc. Advances Diversified Mining Portfolio Anchored by World-Class Copper and Gold

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements. The demand backdrop for what Numa Numa is working to develop is well documented. Numa Numa is pursuing the reconstruction of Panguna as its flagship long-term project, working in partnership with the mine's customary landowners. Taken together, Numa Numa's portfolio reflects a coherent and integrated development strategy rather than a collection of unrelated bets. The global mining industry is under real pressure to find and develop new sources of copper, gold and critical minerals as existing deposits deplete and new large-scale discoveries become harder to bring online.…

WednesdayAug 26, 2026 9:45 am

American Fusion(TM) Inc. (AMFN) Builds Toward Commercial Fusion Market as Texatron(TM) Targets Rising Power Demand and Company Prepares for National Exchange Uplisting

American Fusion is positioning its Texatron(TM) Fusion Engine(TM) for use in distributed power markets where grid constraints are becoming more significant, and has engaged national law firm Lucosky Brookman LLP to advise on a planned uplisting to Nasdaq Capital Market or other senior national exchange, including registration and SEC compliance matters. The global fusion sector attracted a record $4.48 billion in funding during the 12 months through July 2026, according to the Fusion Industry Association. Texas’ expanding artificial-intelligence and data-center economy is creating a growing requirement for reliable electricity, including power that can potentially be generated behind the meter. American…

WednesdayAug 26, 2026 9:00 am

Silynxcom Ltd. (NYSE American: SYNX) Is ‘One to Watch’

Silynxcom is positioned within a tactical headset market where Market Research Future data projects the in-ear segment to grow at a 42% CAGR from 2021 through 2027 as military and law-enforcement users increasingly transition from conventional over-ear systems. The company has developed a differentiated tactical communications platform combining proprietary in-ear voice capture, Hear-Thru situational awareness, hearing protection, modular radio connectivity and newer capabilities addressing drone detection and other evolving battlefield requirements. Silynxcom reported approximately $7.3 million in backlog as of April 30, 2026, exceeding the company’s $5.8 million in total revenue for 2025. Recent military orders and deliveries in Asia…

TuesdayAug 25, 2026 1:50 pm

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Is ‘One to Watch’

FDA-approved LYMPHIR(TM) provides commercial-stage exposure to the oncology market. LYMPHIR(TM) generated $5.6 million in net revenue during the first six months of fiscal 2026 following its December 2025 commercial launch. Late-stage pipeline includes Mino-Lok(R), which met the primary and secondary endpoints of its pivotal Phase 3 trial. Diversified development portfolio targets critical-care indications with significant unmet medical needs. Halo-Lido could potentially become the first FDA-approved prescription product for the treatment of hemorrhoids in the United States. Stem cell platform provides an additional development opportunity targeting acute respiratory distress syndrome. Experienced leadership team has extensive pharmaceutical development, commercialization, sales, marketing and…

Site Search

Company Search

Category: Articles